A new report shows the global market for testing for Methicillin‑resistant Staphylococcus aureus (MRSA) is expected to grow from about $4.3 billion in 2025 to $6.5 billion by 2035. Diagnostic firms report faster test types using PCR and sequencing are driving demand. Because MRSA continues to cause hard-to-treat infections, hospitals and labs are investing more in rapid detection. The faster results enable quicker decisions and may help reduce spread. The scale of the market growth shows how serious healthcare systems view MRSA now.